Here begins the text.

Revisions of PRECAUTIONS

PRECAUTIONS in package inserts include information such as Warning, Contraindications, Important Precautions, and Clinically Significant Adverse Reactions. When a new risk is identified, the Pharmaceuticals and Medical Devices Agency (PMDA) thoroughly investigates the risk and discusses a necessity of revision of PRECAUSIONS with expert advisors so that the PMDA can recommend an additional safety measure to the Ministry of Health, Labour and Welfare (MHLW). Following the investigation results from the PMDA, the MHLW issues a notice to revise PRECAUSIONS. Marketing authorization holders consequently revise PRECAUTIONS according to the notice.

Posted date Nonproprietary name Detailed information on revisions of PRECAUTIONS (from MHLW) Summary of investigation results (from PMDA)
March 30, 2021 Onasemnogene abeparvovec PDF形式 PDF形式
February 25, 2021 Tisagenlecleucel PDF形式 PDF形式


JCN 3010005007409

Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki,
Chiyoda-ku, Tokyo 100-0013 Japan

  • Contact us
  • Access/Map

Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved.

Revisions of PRECAUTIONS